Litcius/Paper detail

Antimicrobial Resistance in Campylobacter coli and Campylobacter jejuni from Human Campylobacteriosis in Taiwan, 2016 to 2019

Ying-Shu Liao, Bo-Han Chen, Ru-Hsiou Teng, You-Wun Wang, Jui-Hsien Chang, Shiu-Yun Liang, Chi-Sen Tsao, Yu-Ping Hong, Hui-Yung Sung, Chien-Shun Chiou

2021Antimicrobial Agents and Chemotherapy43 citationsDOIOpen Access PDF

Abstract

were identified in 24.2%, 21.5%, 33.3%, 11.9%, 96.3%, 10.0%, 0.9%, 6.8%, 3.2%, 13.2%, and 96.3%, respectively. High-level resistance to 8 antimicrobials in isolates was 100% predictable by the known resistance determinants, whereas low-level resistance to azithromycin, clindamycin, nalidixic acid, ciprofloxacin, and florfenicol in isolates was associated with sequence variations in CmeA and CmeB of the CmeABC efflux pump. Resistance-enhancing CmeB variants were identified in 62.1% (136/219) of isolates. In conclusion, an extremely high proportion of C. coli (100%) and C. jejuni (88.3%) were multidrug-resistant, and a high proportion (62.5%) of C. coli isolates were resistant to azithromycin, erythromycin, and clindamycin, which would complicate the treatment of invasive campylobacteriosis in this country.

Topics & Concepts

BiologyCampylobacteriosisCampylobacter jejuniMicrobiologyMultilocus sequence typingCampylobacter coliAntibiotic resistanceCampylobacterNalidixic acid23S ribosomal RNADrug resistanceFlorfenicolMultiple drug resistanceTypingGeneticsSpectinomycinGenotypeWhole genome sequencingBacterial geneticsAntimicrobialVirologyMolecular epidemiologyBroth microdilutionEscherichia coliTetracyclineSalmonella and Campylobacter epidemiologyVeterinary medicine and infectious diseasesAntimicrobial Resistance in Staphylococcus